Unity Biotechnology (NASDAQ:UBX) reported quarterly losses of $(0.19) per share. This is a 40.63 percent increase over losses of $(0.32) per share from the same period last year.
Keybanc Maintains Overweight on Twilio, Lowers Price Target to $77
Keybanc analyst Thomas Blakey maintains Twilio (NYSE:TWLO) with a Overweight and lowers the price target from $96 to $77.